

JOINT WORKING EXECUTIVE SUMMARY



Project Title:

Creation of a Nurse-Led Atopic Dermatitis (NuLAD) Service to run within the Queen Elizabeth Hospital (University Hospitals Birmingham NHS Foundation Trust) for two years, starting on 2nd October, 2023.

Background:

Atopic dermatitis (AD) is a complex, chronic inflammatory condition, which can interfere with patients' daily lives and can also inflict a psychological burden. AD is characterised by a heterogenous clinical phenotype and a range of subtypes. Complex interactions between the environment and the immune system contribute to this heterogeneity.

Itch is one of the most common, bothersome symptoms – which can result in patients suffering from sleep disturbance. Additionally, anxiety and depression are also commonly present. Inadequate disease control and fear of relapse further increases the burden for patients.

AD affects approximately 1.1m adults in the UK (2.5% of the adult population). Poor control of AD has been shown to result in increased healthcare resource utilisation including healthcare provider and emergency department visits and hospital admissions.

Due to limited treatment options for moderate-to-severe AD, there remains a significant unmet need for additional long-term targeted systemic or biological therapies.

Project summary:

This joint working project will provide an opportunity to improve patient identification and management of moderate-to-severe AD patients requiring biologic/systemic treatment at Queen Elizabeth Hospital, Birmingham. LEO Pharma and University Hospitals Birmingham NHS Foundation Trust will pool resources to establish new pathways and a bespoke nurse-led AD clinic. The project will be managed through delivery of milestones leading to development of a business case to continue funding on completion (30th September, 2025) of the project.

Expected benefits of joint working project:

Benefit to patients with AD:

- Faster access to biologic and other novel treatments
- Timely and seamless continuation of treatment
- Increase access to expertise and timely follow up
- Increase support
- Increase compliance and concordance with the medicines
- Improving patient and carer outcomes
- Improve access for vulnerable patients

• **Dermatology**
beyond the skin

LEO Pharma UK/IE

Building 5,
Foundation Park,
Roxborough Way,
Maidenhead, SL6 3UD
www.leo-pharma.co.uk



Benefit to the NHS:

- Increase capacity and access to service
- Decrease in the potential cost of acute care – less flares requiring acute support
- Release consultant time therefore increasing staff utilisation
- Equity of care by a single point of access reducing variability
- Improve patient satisfaction within the service

• Dermatology
beyond the skin

Benefit to LEO Pharma:

- Improve working relationships and reputation with NHS partners
- LEO Pharma demonstrated to be a reliable, solutions-oriented partner supporting the NHS
- Better understanding of the challenges faced by the NHS in delivering high-quality patient services and care
- Potential increase in prescribing of on formulary biologics indicated for AD, if clinically appropriate for patients, which may include LEO Pharma products
- Helps LEO Pharma to live its values of customer focus, integrity, adaptability, innovation, and passion